A study to evaluate the importance of biomarkers a type of blood compounds in determining the disease progression status in patient with Hodgkins lymphoma a type of blood cancer who will receive the standard treatment
Not Applicable
- Conditions
- Health Condition 1: null- Newly diagnosed Hodgkin lymphoma patients
- Registration Number
- CTRI/2017/11/010551
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Newly diagnosed classical Hodgkin lymphoma (Early stage unfavorable and Advanced stage)
2 Treated with ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
3 age > 15 years
Exclusion Criteria
1 Early Stage Favourable
2 HIV positive patient
3 Patients unwilling to comply with the study procedures
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To correlate iPET response with biomarker responseTimepoint: 1 At baseline <br/ ><br>2 After 2 cycles of chemotherapy <br/ ><br>3 At the end of therapy <br/ ><br>4 At the end of 2 yrs
- Secondary Outcome Measures
Name Time Method Correlation of biomarkers response with the PFS at the end of 2 yearsTimepoint: 1 At the end of therapy <br/ ><br>2 At the end of 2 yrs;Correlation of End of Therapy PET with biomaker responseTimepoint: 1 At baseline <br/ ><br>2 After 2 cycles of chemotherapy <br/ ><br>3 At the end of therapy